SE0101980D0 - Pharmaceutical combination - Google Patents

Pharmaceutical combination

Info

Publication number
SE0101980D0
SE0101980D0 SE0101980A SE0101980A SE0101980D0 SE 0101980 D0 SE0101980 D0 SE 0101980D0 SE 0101980 A SE0101980 A SE 0101980A SE 0101980 A SE0101980 A SE 0101980A SE 0101980 D0 SE0101980 D0 SE 0101980D0
Authority
SE
Sweden
Prior art keywords
ethoxy
pharmaceutical combination
phenyl
propanoic acid
methanesulfonyloxyphenyl
Prior art date
Application number
SE0101980A
Other languages
English (en)
Swedish (sv)
Inventor
Peter Oehman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0101980A priority Critical patent/SE0101980D0/xx
Publication of SE0101980D0 publication Critical patent/SE0101980D0/xx
Priority to IL15903302A priority patent/IL159033A0/xx
Priority to US10/478,798 priority patent/US20040152771A1/en
Priority to CNA028149394A priority patent/CN1535144A/zh
Priority to SK1470-2003A priority patent/SK14702003A3/sk
Priority to EEP200300584A priority patent/EE200300584A/xx
Priority to PL02367891A priority patent/PL367891A1/xx
Priority to KR10-2003-7015601A priority patent/KR20040008202A/ko
Priority to EP02728300A priority patent/EP1404309B1/en
Priority to CZ20033234A priority patent/CZ20033234A3/cs
Priority to MXPA03011005A priority patent/MXPA03011005A/es
Priority to EP06000170A priority patent/EP1666034A1/en
Priority to JP2002592913A priority patent/JP2004532864A/ja
Priority to DE60214185T priority patent/DE60214185T2/de
Priority to BR0210128-9A priority patent/BR0210128A/pt
Priority to HK04105673.9A priority patent/HK1062813B/en
Priority to PCT/SE2002/001038 priority patent/WO2002096402A1/en
Priority to ES02728300T priority patent/ES2269686T3/es
Priority to RU2003136154/15A priority patent/RU2003136154A/ru
Priority to CA002448643A priority patent/CA2448643A1/en
Priority to AT02728300T priority patent/ATE336993T1/de
Priority to HU0400946A priority patent/HUP0400946A3/hu
Priority to NO20035237A priority patent/NO20035237D0/no
Priority to ZA200309264A priority patent/ZA200309264B/en
Priority to IS7058A priority patent/IS7058A/is
Priority to CO03112108A priority patent/CO5540375A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
SE0101980A 2001-06-01 2001-06-01 Pharmaceutical combination SE0101980D0 (sv)

Priority Applications (26)

Application Number Priority Date Filing Date Title
SE0101980A SE0101980D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination
HU0400946A HUP0400946A3 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl)ethoxy]phenyl}-(s)-2-ethoxy propanoic acid and a biguanide drug
JP2002592913A JP2004532864A (ja) 2001-06-01 2002-05-30 （Ｓ）−２−エトキシ−３−［４−（２−｛４−メタンスルホニルオキシフェニル｝エトキシ）フェニル］プロパン酸または３−｛４−［２−（４−ｔｅｒｔ−ブトキシカルボニルアミノフェニル）エトキシ］フェニル｝−（Ｓ）−２−エトキシプロパン酸のいずれかおよびビグアニド剤を含む薬剤的組み合わせ
BR0210128-9A BR0210128A (pt) 2001-06-01 2002-05-30 Combinação farmacêutica, método de tratamento ou de prevenção de diabetes, método de tratamento da sìndrome de resistência à insulina, kit de partes, produto combinado, e, método de produção de um produto combinado
CNA028149394A CN1535144A (zh) 2001-06-01 2002-05-30 一种包含(s)-2-乙氧基-3-[4-(2-{4-甲磺酰基氧基苯基}乙氧基)苯基]丙酸或3-{4-[2-（4-叔丁氧基羰基氨基苯基）乙氧基]苯基}-（s）-2-乙氧基丙酸和双胍类药物的联合药物
SK1470-2003A SK14702003A3 (sk) 2001-06-01 2002-05-30 Farmaceutická kombinácia obsahujúca buď kyselinu (S)-2-etoxy-3- [4-(2-{4-metánsulfonyloxyfenyl}-etoxy)fenyl]propánovú, alebo kyselinu 3-{4-[2-(4-terc-butoxykarbonylaminofenyl)etoxy]fenyl}- (S)-2-etoxypropánovú a biguanidové liečivo
EEP200300584A EE200300584A (et) 2001-06-01 2002-05-30 Ravimikombinatsioon, mis sisaldab kas (S)-2-etoksü-3-[4-(2-{4-metaansulfonüüloksüfenüül}etoksü)fenüül]propaanhapet või 3-{4-[2-(4-tert-butoksükarbonüülaminofenüül)etoksü]fenüül}-(S)-2-etoksüpropaanhapet ja biguaniidravimit
PL02367891A PL367891A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- 4-(2- 4-methane sulfonyl oxyphenyl ethoxy) phenyl] propanoic acid or 3- 4- 2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl -(s)-2-ethoxy propanoic acid and a biguanide drug
KR10-2003-7015601A KR20040008202A (ko) 2001-06-01 2002-05-30 (ｓ)-2-에톡시-3-[4-(2-｛4-메탄술포닐옥시페닐｝에톡시)페닐]프로판산 또는3-｛4-[2-(4-ｔ-부톡시카르보닐아미노페닐)에톡시]페닐｝-(ｓ)-2-에톡시 프로판산 및 비구아니드 약물을 포함하는약학 조합물
EP02728300A EP1404309B1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- 4-(2- 4-methane sulfonyl oxyphenyl ethoxy) phenyl| propanoic acid or 3- 4- 2- (4-tert-butoxy carbonyl aminophenyl) ethoxy| phenyl -(s)-2-ethoxy propanoic acid and a biguanide drug
CZ20033234A CZ20033234A3 (cs) 2001-06-01 2002-05-30 Farmaceutická kombinace
MXPA03011005A MXPA03011005A (es) 2001-06-01 2002-05-30 Una combinacion farmaceutica que comprende ya sea acido (s)-2- etoxi-3[4 (2-{4- metansulfonil oxifenil} etoxi)fenil] propanoico o acido 3-(4 -[2-(4-terbutoxicarbonilaminofenil) etoxi] fenil}-(s)- 2-etoxi propanoico y un faramco biguanida.
EP06000170A EP1666034A1 (en) 2001-06-01 2002-05-30 Pharmaceutical combination comprising a biguanide
IL15903302A IL159033A0 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s) -2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl}ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl)ethoxy] phenyl}-(s) -2- ethoxy propanoic acid and a biguanide drug
DE60214185T DE60214185T2 (de) 2001-06-01 2002-05-30 Pharmazeutische kombination mit (s)-2-ethoxy-3-4-(2-4-methansulfonyloxyphenylethoxy) phenyl propansäure oder 3-4-2-(4-tert.-butoxycarbonylaminophenyl) ethoxyphenyl-(s)-2-ethoxypropansäure und einem biguanid-arzneimittel
US10/478,798 US20040152771A1 (en) 2001-06-01 2002-05-30 Pharmaceutical combination comprising either (s)-2-ethoxy-3-[4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy car4bonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and biguanide drug
HK04105673.9A HK1062813B (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- 4-(2- 4-methane sulfonyl oxyphenyl ethoxy) phenyl] propanoic acid or 3-4-2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl -(s)-2-ethoxy propanoic acid and a biguanide drug
PCT/SE2002/001038 WO2002096402A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug
ES02728300T ES2269686T3 (es) 2001-06-01 2002-05-30 Una combinacion farmaceutica que comprende acido (s)-2-etoxi-3-(4-(2-(4-metanosulfoniloxifenil)etoxi)fenil)propanoico o acido 3-(4-(2-(4-terc-butoxicarbonilaminofenil)etoxi)fenil)-(s)-2-etoxipropanoico y un farmaco de biguanida.
RU2003136154/15A RU2003136154A (ru) 2001-06-01 2002-05-30 Фармацевтическая комбинация, содержащая либо (s)-2-этокси-3-[4-(2-{4-метансульфонилоксифенил}этокси)фенил]-пропионовую кислоту, либо 3-{4-[2-(4-третбутоксикарбониламинофенил)этокси]фенил}-(s)-этоксипропионов ую кислоту и бигуанидное лекарственное средство
CA002448643A CA2448643A1 (en) 2001-06-01 2002-05-30 A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a biguanide drug
AT02728300T ATE336993T1 (de) 2001-06-01 2002-05-30 Pharmazeutische kombination mit (s)-2-ethoxy-3-4- (2-4-methansulfonyloxyphenylethoxy) phenyl propansäure oder 3-4-2-(4-tert.- butoxycarbonylaminophenyl) ethoxyphenyl-(s)-2- ethoxypropansäure und einem biguanid-arzneimittel
NO20035237A NO20035237D0 (no) 2001-06-01 2003-11-25 Farmasöytisk kombinasjon omfattende enten (S) -2-etoksy-3-(4- (2- (4-metansulfonyloksyfenyl) etoksy) fenyl) propansyre eller 3- (4- (2- (4-tert-butoksykarbonylaminofenyl) etoksy) fenyl)
ZA200309264A ZA200309264B (en) 2001-06-01 2003-11-27 A pharmaceutical combination comprising either (S)-2-ethoxy-3-[4-(2- {4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-[ (4-tert-butoxy carbonyl aminophenyl) ethoxy]phenyl} -(S)-2-ethoxy propanoic acid and a biguanide drug.
IS7058A IS7058A (is) 2001-06-01 2003-11-28 Lyfjablanda sem annaðhvort felur í sér (S)-2-etoxý-3-[4-(2-{4-metansúlfónýloxýfenýl} etoxý)fenýl] própansýru eða 3-{4-[2-(4-tert-bútoxýkarbónýlamínófenýl)etoxý]fenýl}-(S)-2-etoxýprópansýru og bígúaníðlyf
CO03112108A CO5540375A2 (es) 2001-06-01 2003-12-23 Una combinacion farmaceutica que comprende uno cualquiera de acido (s)-2-etoxi-3-(4-(2-(4-metanosulfoniloxifenil) etoxi) fenil)propanoico o acido 3-(4-(2-(4-tert- butoxicarbonilaminofenil)etoxi)fenil)-(s)-2-etoxi propanoico y un farmaco de biguanida

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101980A SE0101980D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
SE0101980D0 true SE0101980D0 (sv) 2001-06-01

Family

ID=20284362

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101980A SE0101980D0 (sv) 2001-06-01 2001-06-01 Pharmaceutical combination

Country Status (24)

Country Link
US (1) US20040152771A1 (cs)
EP (2) EP1666034A1 (cs)
JP (1) JP2004532864A (cs)
KR (1) KR20040008202A (cs)
CN (1) CN1535144A (cs)
AT (1) ATE336993T1 (cs)
BR (1) BR0210128A (cs)
CA (1) CA2448643A1 (cs)
CO (1) CO5540375A2 (cs)
CZ (1) CZ20033234A3 (cs)
DE (1) DE60214185T2 (cs)
EE (1) EE200300584A (cs)
ES (1) ES2269686T3 (cs)
HU (1) HUP0400946A3 (cs)
IL (1) IL159033A0 (cs)
IS (1) IS7058A (cs)
MX (1) MXPA03011005A (cs)
NO (1) NO20035237D0 (cs)
PL (1) PL367891A1 (cs)
RU (1) RU2003136154A (cs)
SE (1) SE0101980D0 (cs)
SK (1) SK14702003A3 (cs)
WO (1) WO2002096402A1 (cs)
ZA (1) ZA200309264B (cs)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201513857A (zh) * 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6552055B2 (en) * 1996-12-11 2003-04-22 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
SE9801990D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
PT1145717E (pt) * 2000-04-13 2004-08-31 Pfizer Prod Inc Efeito sinergistico de gliburide e milrinona

Also Published As

Publication number Publication date
IL159033A0 (en) 2004-05-12
EP1666034A1 (en) 2006-06-07
EE200300584A (et) 2004-02-16
DE60214185T2 (de) 2007-07-19
CA2448643A1 (en) 2002-12-05
PL367891A1 (en) 2005-03-07
RU2003136154A (ru) 2005-02-10
CO5540375A2 (es) 2005-07-29
ES2269686T3 (es) 2007-04-01
HK1062813A1 (en) 2004-11-26
DE60214185D1 (en) 2006-10-05
IS7058A (is) 2003-11-28
WO2002096402A1 (en) 2002-12-05
MXPA03011005A (es) 2004-02-27
EP1404309B1 (en) 2006-08-23
CN1535144A (zh) 2004-10-06
BR0210128A (pt) 2004-06-08
KR20040008202A (ko) 2004-01-28
ZA200309264B (en) 2005-02-28
EP1404309A1 (en) 2004-04-07
NO20035237D0 (no) 2003-11-25
US20040152771A1 (en) 2004-08-05
JP2004532864A (ja) 2004-10-28
HUP0400946A2 (hu) 2004-08-30
ATE336993T1 (de) 2006-09-15
CZ20033234A3 (cs) 2004-12-15
HUP0400946A3 (en) 2007-11-28
SK14702003A3 (sk) 2004-09-08

Similar Documents

Publication Publication Date Title
BR9910913A (pt) Composto, processo para a preparação de um composto, formulação farmacêutica, uso de um composto, e, processo para a profilaxia e/ou tratamento de condições clìnicas associadas com resistência a insulina
HRP20090229T1 (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate
DK1237855T3 (da) Krystallinsk form af (S)-2-ethoxy-3-[4-(2-(4-methansulfonyloxyphenyl)ethoxy)phenyl]propansyre
DK1370543T3 (da) Bredspektrede 2-(substitueret amino) benzothiazol- sulfonamid-HIV-proteaseinhibitorer
NO20003069D0 (no) 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl]tiazolidin- 2,4-dion-maleinsyre-salt-hydrat som farmasøytikum
IS8224A (is) Amínsölt (-)-2-{[2-(4-hýdroxýfenýl)etýl]-þíó}-3-[4-(2-{4-[(metýlsúlfónýl)oxý]fenoxý}etýl)fenýl]própansýru og notkun þeirra í læknisfræði
SE0101980D0 (sv) Pharmaceutical combination
BR0110399A (pt) Composição herbicida sólida
SE0101981D0 (sv) Pharmaceutical combination
SE0101982D0 (sv) Pharmaceutical combination
RS52014B (sr) Nova so benzoilgvanidina
NO20000665L (no) 2-{3-[4-(2-t-Butyl-6-trifluormetyl-4-pyrimidinyl)-1- piperazinyl]propyltio}-4-pyrimidinol-fumarat
HK1062527A (en) A pharmaceutical combination comprising either (s)-2-ethoxy-3- [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy) phenyl] propanoic acid or 3-{4-[2-(4-tert-butoxy carbonyl aminophenyl) ethoxy] phenyl} -(s)-2-ethoxy propanoic acid and a sulonylurea
BR0312242A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida para o tratamento da fibrose pulmonar
IL172440A0 (en) Potassium or sodium salt of (-)-2-{[2-(4-hydroxyphenyl) ethyl]thio}-3-[4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]propanoic acid and their use in medicine
WO2004026930A3 (en) The method for reducing inflammation using sti-571 or its salt
HK1087690A (en) Amine salts of (-)-2-{'2-(4-hydroxyphenyl) ethyl!-thio}-3-'4-(2-{4-'(methylsulfonyl)oxy!phenoxy}ethyl)phenyl! propanoic acid and their use in medicine
DE60142063D1 (de) (2s)-2-(adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propion säureisopropylester, dessen herstellung und dessen verwendung
HK1087395A (en) Process for the preparation of racemic 2-{[2-(4-hydroxyphenyl)ethyl]thio} -3-{4-(2-{4-[(methylsulfonyl)oxy]phenoxy}ethyl)phenyl]-propanoic acid
AU2001290743A1 (en) Solid salt forms of n-(2-(4-(2-(1-methylethoxy)phenyl)-1-piperazinyl)ethyl)-2-oxo-1-piperidineacetamide
HK1087396A (en) Potassium or sodium salt of (-)-2- {'2-(4-hydroxyphenyl)ethyl]-thio -3-'4-(2- {4-'(methylsulfonyl)oxy ]phenoxy }phenyl]propanoic acid and their use in medicine.